semagacestat
Jump to navigation
Jump to search
Indications
- developed to treat Alzheimer's disease
- development halted in phase 3 trials
Adverse effects
- may worsen cognition in Alzheimer's patients
- increased risk of skin cancer
Mechanism of action
- inhibits APP gamma-secretase
More general terms
References
- ↑ MSNBC, Reuters, 8/17/2010 http://www.msnbc.msn.com/id/38737158/ns/health-alzheimers_disease
- ↑ Doody RS et al. A Phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013 Jul 25; 369:341 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23883379